Taiwan · Delayed Price · Currency is TWD Orient Pharma Statistics
Total Valuation
Orient Pharma has a market cap or net worth of TWD 6.00 billion. The enterprise value is 5.66 billion.
| Market Cap | 6.00B |
| Enterprise Value | 5.66B |
Important Dates
The last earnings date was Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Orient Pharma has 243.04 million shares outstanding. The number of shares has increased by 1.06% in one year.
| Current Share Class | 243.04M |
| Shares Outstanding | 243.04M |
| Shares Change (YoY) | +1.06% |
| Shares Change (QoQ) | +4.19% |
| Owned by Insiders (%) | 1.96% |
| Owned by Institutions (%) | n/a |
| Float | 54.95M |
Valuation Ratios
The trailing PE ratio is 43.50.
| PE Ratio | 43.50 |
| Forward PE | n/a |
| PS Ratio | 4.70 |
| PB Ratio | 2.43 |
| P/TBV Ratio | 2.93 |
| P/FCF Ratio | 21.83 |
| P/OCF Ratio | 18.89 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.51, with an EV/FCF ratio of 20.58.
| EV / Earnings | 44.21 |
| EV / Sales | 4.43 |
| EV / EBITDA | 17.51 |
| EV / EBIT | 29.82 |
| EV / FCF | 20.58 |
Financial Position
The company has a current ratio of 5.33, with a Debt / Equity ratio of 0.08.
| Current Ratio | 5.33 |
| Quick Ratio | 3.58 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.62 |
| Debt / FCF | 0.73 |
| Interest Coverage | 18.63 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 7.12% |
| Revenue Per Employee | 7.39M |
| Profits Per Employee | 739,827 |
| Employee Count | 173 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Orient Pharma has paid 52.77 million in taxes.
| Income Tax | 52.77M |
| Effective Tax Rate | 29.19% |
Stock Price Statistics
The stock price has decreased by -33.33% in the last 52 weeks. The beta is 0.04, so Orient Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.04 |
| 52-Week Price Change | -33.33% |
| 50-Day Moving Average | 25.31 |
| 200-Day Moving Average | 31.06 |
| Relative Strength Index (RSI) | 50.64 |
| Average Volume (20 Days) | 148,597 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orient Pharma had revenue of TWD 1.28 billion and earned 127.99 million in profits. Earnings per share was 0.57.
| Revenue | 1.28B |
| Gross Profit | 700.24M |
| Operating Income | 189.76M |
| Pretax Income | 180.76M |
| Net Income | 127.99M |
| EBITDA | 303.58M |
| EBIT | 189.76M |
| Earnings Per Share (EPS) | 0.57 |
Balance Sheet
The company has 545.13 million in cash and 200.57 million in debt, giving a net cash position of 344.56 million or 1.42 per share.
| Cash & Cash Equivalents | 545.13M |
| Total Debt | 200.57M |
| Net Cash | 344.56M |
| Net Cash Per Share | 1.42 |
| Equity (Book Value) | 2.47B |
| Book Value Per Share | 10.18 |
| Working Capital | 961.53M |
Cash Flow
In the last 12 months, operating cash flow was 317.86 million and capital expenditures -42.85 million, giving a free cash flow of 275.01 million.
| Operating Cash Flow | 317.86M |
| Capital Expenditures | -42.85M |
| Free Cash Flow | 275.01M |
| FCF Per Share | 1.13 |
Margins
Gross margin is 54.80%, with operating and profit margins of 14.85% and 10.02%.
| Gross Margin | 54.80% |
| Operating Margin | 14.85% |
| Pretax Margin | 14.15% |
| Profit Margin | 10.02% |
| EBITDA Margin | 23.76% |
| EBIT Margin | 14.85% |
| FCF Margin | 21.52% |
Dividends & Yields
Orient Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.06% |
| Shareholder Yield | -1.06% |
| Earnings Yield | 2.13% |
| FCF Yield | 4.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 23, 2016. It was a reverse split with a ratio of 0.6500936135.
| Last Split Date | May 23, 2016 |
| Split Type | Reverse |
| Split Ratio | 0.6500936135 |
Scores
Orient Pharma has an Altman Z-Score of 11.8 and a Piotroski F-Score of 4.
| Altman Z-Score | 11.8 |
| Piotroski F-Score | 4 |